A new study has stated that the anti-retroviral treatment for HIV positive persons should start earlier than usual as it sharply improves their survival rates.
Researchers say analysis of thousands of HIV-positive patients between 1996 and 2006 found a 71-percent higher risk of death for those who delayed treatment compared with those initiating early highly active anti-retroviral therapy (HAART), the National Institutes of Health (NIH) reported Sunday.
AIDS/HIV - Health Education
Encyclopedia section of medindia gives general info about AIDS information and health education.
Advertisement
The study, led by Mari Kitahata of the University of Washington-Seattle, looked at 8,374 patients whose CD4+ T-cells - key "helper" cells in the body's immune system - were between 351 and 500 cells per square millimeter in blood.
Thirty percent of subjects in the study began taking HAART right away, while 70 percent waited until their T-cell count dropped below 350, when the immune system is considered seriously compromised.
![AIDS / HIV - Treatment]( "AIDS / HIV - Treatment")
Encyclopedia section of medindia explains in brief about the treatment for AIDS/HIV
"The researchers found a 71 percent higher risk of death for patients who deferred treatment rather than initiating HAART, suggesting that therapy should begin at an earlier stage of HIV disease than currently recommended," NIH said in a statement.
The optimal timing for the introduction of HAART therapy - a combination of at least three HIV medicines - has been a point of contention for more than a decade, with some doctors suggesting holding off treatment as long as possible in order to spare patients the side effects of AIDS drugs.
Up to now, guidelines had recommended that HIV treatment begin when a person's T-cell count dropped below 350.
"The data are rather compelling that the risk of death appears to be higher if you wait than if you treat," Anthony Fauci, director of NIH's National Institute of Allergy and Infectious Diseases which sponsored part of the research.
The findings were presented Sunday at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington.
Lead researcher Kitahata said the findings were striking because of the "magnitude" of the difference in survival rate between the two groups, according to USA Today.
"Seventy percent is a significant and substantial increase in the risk of death," the daily quoted Kitahata as saying.
According to the World Health Organization, 33 million people around the world are infected with the AIDS virus, mostly in sub-Saharan Africa. One million HIV-infected people live in the United States.
Some two million people died worldwide of AIDS in 2007.
On Monday the world body sharply cut an earlier mortality forecast, saying the latest forecast now expects deaths to rise from 2.2 million in 2008 to a maximum of 2.4 million in 2012, before declining to 1.2 million in 2030.
An earlier WHO projection had HIV and AIDS deaths would rise to 6.5 million in 2030.
Source: AFP
TAN/L
AIDS / HIV - Treatment
Encyclopedia section of medindia explains in brief about the treatment for AIDS/HIV
Advertisement
"The researchers found a 71 percent higher risk of death for patients who deferred treatment rather than initiating HAART, suggesting that therapy should begin at an earlier stage of HIV disease than currently recommended," NIH said in a statement.
The optimal timing for the introduction of HAART therapy - a combination of at least three HIV medicines - has been a point of contention for more than a decade, with some doctors suggesting holding off treatment as long as possible in order to spare patients the side effects of AIDS drugs.
Up to now, guidelines had recommended that HIV treatment begin when a person's T-cell count dropped below 350.
"The data are rather compelling that the risk of death appears to be higher if you wait than if you treat," Anthony Fauci, director of NIH's National Institute of Allergy and Infectious Diseases which sponsored part of the research.
The findings were presented Sunday at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington.
Lead researcher Kitahata said the findings were striking because of the "magnitude" of the difference in survival rate between the two groups, according to USA Today.
"Seventy percent is a significant and substantial increase in the risk of death," the daily quoted Kitahata as saying.
According to the World Health Organization, 33 million people around the world are infected with the AIDS virus, mostly in sub-Saharan Africa. One million HIV-infected people live in the United States.
Some two million people died worldwide of AIDS in 2007.
On Monday the world body sharply cut an earlier mortality forecast, saying the latest forecast now expects deaths to rise from 2.2 million in 2008 to a maximum of 2.4 million in 2012, before declining to 1.2 million in 2030.
An earlier WHO projection had HIV and AIDS deaths would rise to 6.5 million in 2030.
Source: AFP
TAN/L
AIDS/HIV - Prevention And Transmission
Encyclopedia section of medindia explains in brief about the prevention for AIDS/HIV
Advertisement
Advertisement
|
Advertisement
Latest AIDS/HIV News
Though monkeypox can affect anyone, CDC research states that approximately 40% of people diagnosed with monkeypox in the US also test positive for HIV.
The Phase 1 trial for a preventive HIV vaccine candidate has initiated enrollment in both the United States and South Africa.
In the United States, African American women make up only 26% of female PrEP users, yet they account for 57% of new infections among women.
Scientists have made a groundbreaking discovery in the fight against HIV/AIDS with the successful resolution of the enigmatic immune-evading HIV protein complex.
Tailored quit-smoking programs are designed to address the risks associated with comorbidity in individuals living with HIV.